The CD40/CD40L costimulatory pathway in inflammatory bowel disease

Gut

Volumn 53, Issue 7, 2004, Pages 1035-1043

  Danese, S ^a,b   Sans, M ^a   Fiocchi, C ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CYTOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; APOPTOSIS; B LYMPHOCYTE ACTIVATION; CHRONIC INFLAMMATION; CYTOKINE RELEASE; EFFECTOR CELL; ENTERITIS; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR INTERACTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; REVIEW; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ANIMALS; ANTIGENS, CD40; CD40 LIGAND; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, MUCOSAL; INFLAMMATORY BOWEL DISEASES; SIGNAL TRANSDUCTION;

EID: 3042614161     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.026278     Document Type: Review

References (53)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205.
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.
3. Koutrobakis I, Manousos ON, Mewwissen SGM, et al. Environmental risk factors in inflammatory bowel disease. Hepatogastroenterology 1996;43:381-93.
4. Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 2003;124:521-36.
5. Monteleone I, Vavassori P, Biancone L, et al. Immunoregulation in the gut: success and failures in human disease. Gut 2002;50(suppl III):iii60-4.
6. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002;2:116-26.
7. Grewal IS, Flavell RA. CD40 and CD154 on cell-mediated immunity. Annu Rev Immunol 1998;16:111-35.
8. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000;67:2-17.
9. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001;58:4-43.
10. Maerten P, Liu Z, Ceuppens JL. Targeting of costimulatory molecules as a therpeutic approach in inflammatory bowel disease. Biodrugs 2003;17:395-411.
11. Lederman S, Yellin MJ, Krichevsky A, et al. Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help). J Exp Med 1992;175:1091-101.
12. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994;76:956-62.
13. Pietravalle F, Lecoanet-Henchoz S, Blasey H, et al. Human native soluble CD40L is a biologically activer trimer, processed inside microsomes. J Biol Chem 1996;271:5965-7.
14. Grammer AC, Lipsky PE. CD40-mediated regulation of immune responses by TRAF-dependent and TRAF-independent signaling mechanisms. Adv Immunol 2001;76:61-178.
15. Zan H, Cerutti A, Dramitinos P, et al. CD40 engagement triggers switching to IgA1 and IgA2 in human B cells through induction of endogenous TGF-beta: evidence for TGF-beta but not IL-10-dependnet direct S mu→S alpha and sequential S mu→S gamma, S gamma→A alpha DNA recombination. J Immunol 1998;161:5217-25.
16. Callard RE, Armitage RJ, Fanslow WC, et al. CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunol Today 1993;14:559-64.
17. Xu J, Foy TM, Laman JD, et al. Mice deficient for the CD40 ligand. Immunity 1994;1:423-31.
18. Grewal IS, Xu J, Flavell RA. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 1998;378:617-20.
19. Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994;180:1263-72.
20. Roy M, Aruffo A, Ledbetter J, et al. Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Eur J Immunol 1995;25:596-603.
21. Cella M, Scheidegger D, Palmer-Lehman K, et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhnaces T cell stimulatory capacity T-T help via APC activation. J Exp Med 1996;184:747-52.
22. Blair PJ, Riley JL, Harlan DM, et al. CD40 ligand (CD154) triggers a short-term CD4+ T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med 2000;191:651-60.
23. + T cell memory. Science 2002;297:2060-3.
24. Yellin MJ, Winikoff S, Fortune SM, et al. Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM-1) up-regulation and IL-6 production and proliferation. J Leukoc Biol 1995;58:209-16.
25. Karmann K, Hughes CCH, Schechner J, et al. CD40 on human endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA 1995;92:4342-6.
26. Dechanet J, Grosset C, Taupin J-L, et al. CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells. J Immunol 1997;159:5640-7.
27. Mach F, Schonbeck U, Fabunmi RP, et al. T lymphocytes induce endothelial cell matrix metalloprofeinase expression by a CD40L-dependent mechanism. Am J Pathol 1999;154:229-38.
28. Thienel U, Loike J, Yellin MJ. CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets. Cell Immunol 1999;198:87-95.
29. Zhang Y, Cao HJ, Graf B, et al. CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts. J Immunol 1998;160:1053-7.
30. Inwald DP, McDowall A, Peters MJ, et al. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003;92:944-6.
31. Danese S, de la Motte C, Rivera-Reyes BM, et al. T-cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol 2004;172:2011-15.
32. Melter M, Reinders MEJ, Sho M, et al. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 2000;96:3801-8.
33. Cho C-S, Cho M-L, Min S-Y, et al. CD40 engagement on synovial fibroblasts up-regulates production of vascular endothelial growth factor. J Immunol 2000;164:5055-61.
34. Battaglia E, Biancone L, Resegotti A, et al. Expression of CD40 and its ligand, CD40L, in intestinal lesions or Crohn's disease. Am J Gastroenterol 1999;94:3279-84.
35. Polese L, Angriman I, Cecchetto A, et al. The role of CD40 in ulcerative colitis: histochemical analysis and clinical correlation. Eur J Gastroenterol Hepatol 2002;14:237-41.
36. Gelbmann CM, Leeb SN, Vogel D, et al. Inducible CD40 expression mediates NFB activation and cytokine secretion in human colonic fibroblasts. Gut 2003;52:1448-56.
37. Vogel JD, West GA, Sturm A, et al. CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokines causing T-cell transmigration. Gastroenterology 2004;126:63-80.
38. Liu Z, Colpaert S, D'Haens GR, et al. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J Immunol 1999;163:4049-57.
39. Danese S, de la Motte C, Sturm A, et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology 2003;124:1249-64.
40. Danese S, Katz JA, Saibeni S, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003;52:1435-41.
41. Sawada-Hase N, Kiyohara T, Miyagawa J, et al. An increased number of CD40-high monocytes in patients with Crohn's disease. Am J Gastroenterol 2000;95:1516-23.
42. Ludwiczek O, Kaser A, Tilg H. Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases. Int J Colorectal Dis 2003;18:142-7.
43. Vogel JD, Majors A, Sturm A, et al. Collagen synthesis by human intestinal fibroblasts (HIF) is modulated by T-cells through the CD40/CD40 ligand (CD40L) pathway. Gastroenterology 2001;120:A135.
44. Monk NJ, Hargreaves REG, Marsh JE, et al. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nat Med 2003;9:1275-80.
45. Stuber E, Strober W, Neurath M. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of helper T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med 1996;183:693-8.
46. high CD4+ T cells by blocking the CD40-CD154 interactions. J Immunol 2000;164:6005-14.
47. de Jong Y, Comiskey M, Kalled SL, et al. Chronic murine colitis is dependent on the CD154/CD40 pathway and can be attenuated by anti-CD154 administration. Gastroenterology 2000;119:715-23.
48. Cong BY, Weaver CT, Lazenby A, et al. Colitis induced by enteric bacterial antigen-specific CD4+ T cells requires CD40-CD40 ligand interactions for a sustained increase in mucosal IL-12. J Immunol 2000;165:2173-82.
49. Li W, Buzoni-Gatel D, Debbobi H, et al. CD40/CD154 ligation is required for the development of acute ileitis following oral infection with an intracellular pathogen in mice. Gastroenterology 2002;122:762-73.
50. Dumont FJ. IDEC-131. IDEC/Eisai. Curr Opin Invest Drugs 2002;3:725-34.
51. Kalunian KC, Davis JC, Merrill JT, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo controlled trial. Arthritis Rheum 2002;46:3251-8.
52. Grammer AC, Slota R, Fischer R, et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003;112:1506-20.
53. Kelsoe G. Therapeutic CD154 antibody for lupus: promise for the future? J Clin Invest 2003;112:1480-2.